LL-37 vs KPV
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Cathelicidin, CAP18
LL-37 is the only cathelicidin antimicrobial peptide humans make, a 37-amino-acid, positively charged, helical fragment cut from a precursor protein called hCAP-18. It is a frontline player in the innate immune system, part of the body's chemical defense against bacteria, viruses, and fungi. This is mainstream, heavily studied human biology, not a fringe research peptide, though LL-37 itself is not an approved drug.
Also: Lys-Pro-Val, Alpha-MSH fragment
KPV is a tiny tripeptide, just three amino acids (lysine, proline, valine), that forms the tail end of the natural hormone alpha-MSH. It is studied almost entirely as an anti-inflammatory agent, particularly for gut and skin inflammation. There are no registered human clinical trials proving its benefits in people; the evidence base is cell-culture and animal studies, so anything you read about it treating disease is preliminary.
Key Comparison Insights
- Both peptides belong to the Immune category, suggesting similar primary applications.
- LL-37 has stronger research evidence (Human Trials) compared to KPV (Animal Studies).
Detailed Comparison
| Attribute | LL-37 | KPV |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | LL-37 carries a net positive charge and has a water-loving and fat-loving (amphipathic) structure, which lets it home in on the negatively charged membranes of bacteria and physically punch holes in them. But killing microbes directly is only half the job. It also acts as a signaling molecule: it neutralizes bacterial toxin LPS, calms or tunes the inflammatory response, recruits immune cells to wounds and infection sites, and helps skin re-grow and close over injuries. It is produced by skin, gut, lung, and other epithelial cells, plus immune cells like neutrophils. This dual role, direct antimicrobial plus immune coordinator, is why it is described as a multifunctional host-defense peptide. | What makes KPV interesting is how it gets into cells. Research suggests it hitches a ride on a nutrient transporter called PepT1, which is normally found in the small intestine but gets switched on in the colon during inflammation. Once inside the cell, KPV appears to interfere with NF-kB, a master switch that turns on inflammatory genes, which in lab studies reduces output of pro-inflammatory signals like TNF-alpha, IL-1beta, and IL-6. Unlike its parent hormone alpha-MSH, KPV does not seem to activate the classic melanocortin receptors, so its proposed action is described as largely receptor-independent. These mechanisms are supported by laboratory work but should be treated as a working model, not settled fact. |
| Common Dosing | 100-200 mcg daily Once daily | 200-500 mcg daily 1-2x daily |
| Administration | Subcutaneous injection or topical | Subcutaneous injection or oral (capsules) |
| Typical Duration | Variable by protocol | 4-8 weeks typical |
| Best Time to Take | Morning | Morning or as directed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The basic biology of LL-37 is well established across many peer-reviewed studies. Its broad antimicrobial activity, membrane-disrupting mechanism, and tissue distribution are documented in reviews such as those in the Journal of Leukocyte Biology and PMC-indexed updates on how it limits the spread of local infection. Research has also explored more speculative directions: LL-37 and engineered mimics have shown anticancer activity in laboratory models, and it has been studied as a possible host-defense factor against Helicobacter pylori in the stomach and against pathogens on the surface of the eye. The important honesty point is that almost all of this is mechanistic and preclinical. LL-37 is firmly proven as a natural part of human immunity, but as a deliberately administered therapy it has not cleared large human clinical trials, and its dual nature means it can also drive inflammation in some disease states. So: rock-solid as biology, still experimental as a treatment. | The honest picture: KPV's reputation rests on animal and in vitro research, not human trials. A frequently cited study in Gastroenterology (Dalmasso and colleagues, 2008) showed PepT1-mediated uptake of KPV reduced intestinal inflammation, and oral KPV lessened chemically induced colitis (DSS and TNBS models) in mice while lowering pro-inflammatory cytokines. A later 2016 study in PMC reported KPV also reduced tumor number in a mouse model of colitis-associated cancer in a PepT1-dependent way. These are genuinely interesting, reproducible animal findings. But there are no published randomized controlled trials in humans for inflammatory bowel disease, eczema, or any of the conditions it is marketed for. Claims that it treats Crohn's, leaky gut, or mast cell activation in people are extrapolations from rodent data, not proven outcomes. |
Frequently Asked Questions: LL-37 vs KPV
What is the difference between LL-37 and KPV?
LL-37 is a immune peptide that ll-37 is the only cathelicidin antimicrobial peptide humans make, a 37-amino-acid, positively charged, helical fragment cut from a precursor protein called hcap-18. it is a frontline player in the innate immune system, part of the body's chemical defense against bacteria, viruses, and fungi. this is mainstream, heavily studied human biology, not a fringe research peptide, though ll-37 itself is not an approved drug. KPV is a immune peptide that kpv is a tiny tripeptide, just three amino acids (lysine, proline, valine), that forms the tail end of the natural hormone alpha-msh. it is studied almost entirely as an anti-inflammatory agent, particularly for gut and skin inflammation. there are no registered human clinical trials proving its benefits in people; the evidence base is cell-culture and animal studies, so anything you read about it treating disease is preliminary. The main differences lie in their mechanisms of action and clinical applications.
Which is better, LL-37 or KPV?
Neither is universally "better" - the choice depends on your specific goals. LL-37 is typically used for immune purposes, while KPV is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can LL-37 and KPV be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using LL-37 and KPV together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.